VolitionRx Statistics
Total Valuation
VolitionRx has a market cap or net worth of $86.30 million. The enterprise value is $91.07 million.
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025, after market close.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
VolitionRx has 103.02 million shares outstanding. The number of shares has increased by 17.60% in one year.
| Current Share Class | 103.02M |
| Shares Outstanding | 103.02M |
| Shares Change (YoY) | +17.60% |
| Shares Change (QoQ) | +3.11% |
| Owned by Insiders (%) | 7.71% |
| Owned by Institutions (%) | 12.80% |
| Float | 71.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 46.26 |
| Forward PS | 16.95 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 69.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.40
| Current Ratio | 0.40 |
| Quick Ratio | 0.34 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -67.15 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -108.04% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -9,783.93% |
| Revenue Per Employee | $15,392 |
| Profits Per Employee | -$282,638 |
| Employee Count | 85 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +37.33% in the last 52 weeks. The beta is 1.06, so VolitionRx's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 |
| 52-Week Price Change | +37.33% |
| 50-Day Moving Average | 0.56 |
| 200-Day Moving Average | 0.61 |
| Relative Strength Index (RSI) | 64.76 |
| Average Volume (20 Days) | 344,797 |
Short Selling Information
The latest short interest is 181,854, so 0.18% of the outstanding shares have been sold short.
| Short Interest | 181,854 |
| Short Previous Month | 346,718 |
| Short % of Shares Out | 0.18% |
| Short % of Float | 0.25% |
| Short Ratio (days to cover) | 0.61 |
Income Statement
In the last 12 months, VolitionRx had revenue of $1.31 million and -$24.02 million in losses. Loss per share was -$0.27.
| Revenue | 1.31M |
| Gross Profit | 1.31M |
| Operating Income | -24.16M |
| Pretax Income | -34.91M |
| Net Income | -24.02M |
| EBITDA | -23.06M |
| EBIT | -24.16M |
| Loss Per Share | -$0.27 |
Full Income StatementBalance Sheet
The company has $2.60 million in cash and $7.37 million in debt, giving a net cash position of -$4.77 million or -$0.05 per share.
| Cash & Cash Equivalents | 2.60M |
| Total Debt | 7.37M |
| Net Cash | -4.77M |
| Net Cash Per Share | -$0.05 |
| Equity (Book Value) | -29.03M |
| Book Value Per Share | -0.28 |
| Working Capital | -4.98M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$21.85 million and capital expenditures -$250,498, giving a free cash flow of -$22.10 million.
| Operating Cash Flow | -21.85M |
| Capital Expenditures | -250,498 |
| Free Cash Flow | -22.10M |
| FCF Per Share | -$0.21 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -1,846.75% |
| Pretax Margin | -1,854.43% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VolitionRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.60% |
| Shareholder Yield | -17.60% |
| Earnings Yield | -27.84% |
| FCF Yield | -25.61% |
Analyst Forecast
The average price target for VolitionRx is $3.88, which is 363.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.88 |
| Price Target Difference | 363.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 176.02% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
VolitionRx has an Altman Z-Score of -47.57 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -47.57 |
| Piotroski F-Score | 2 |
